A Phase 3 interventional study of 0.135mg MAP0010 and 0.25mg MAP0010 in Asthma, sponsored by Allergan. Terminated. Open to participants aged 12 Months to 8 Years. Per ClinicalTrials.gov, last updated 2014-01-09.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 48th largest by enrollment of the 108 interventional ones that give a count, is one of 7 that started in 2008, is one of 51 in phase 3, and was the 55th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Months to 8 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
11 studies in Asthma by AbbVie: none open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Asthma by AbbVie, this one is the 4th largest by enrollment, is the only one that started in 2008, is one of 2 in phase 3, and was the 6th registered.
AbbVie’s Asthma studies by the year they started, since 2005.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 11 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Drug: 0.135mg MAP0010
0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Drug: 0.25mg MAP0010
0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Number of Patients With Treatment Emergent Adverse Events Related to Study Drug
A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.
Time frame: 40 weeks
Number of Patients Reporting at Least One Treatment Emergent Adverse Event Leading to Study Termination
A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.
Time frame: 40 weeks
| Milestone | 0.135mg MAP0010 | 0.25mg MAP0010 |
|---|---|---|
| Started | 94 | 98 |
| Completed | 45 | 44 |
| Not completed | 49 | 54 |
A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.
| participants | 0.135mg MAP0010 | 0.25mg MAP0010 |
|---|---|---|
| Number of Patients With Treatment Emergent Adverse Events Related to Study Drug | 6 | 4 |
A treatment emergent adverse event is one with a start date on or after the date of first administration of the study drug during the study.
| participants | 0.135mg MAP0010 | 0.25mg MAP0010 |
|---|---|---|
| Number of Patients Reporting at Least One Treatment Emergent Adverse Event Leading to Study Termination | 8 | 7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.135mg MAP0010 | — | 0/94 (0%) | 71/94 (75.5%) |
| 0.25mg MAP0010 | — | 1/98 (1%) | 85/98 (86.7%) |
| Event | 0.135mg MAP0010 | 0.25mg MAP0010 |
|---|---|---|
| Acquired hydroceleReproductive system and breast disorders | 0/94 | 1/98 |
| Event | 0.135mg MAP0010 | 0.25mg MAP0010 |
|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 17/94 | 32/98 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 19/94 | 12/98 |
| PyrexiaGeneral disorders | 4/94 | 12/98 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 3/94 | 11/98 |
| Pharyngitis streptococcalInfections and infestations | 10/94 | 5/98 |
| SinusitisInfections and infestations | 7/94 | 2/98 |
| PharyngitisInfections and infestations | 2/94 | 6/98 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/94 | 6/98 |
| NasopharyngitisInfections and infestations | 5/94 | 4/98 |
| RhinitisInfections and infestations | 2/94 | 5/98 |
Subjects were randomly assigned to treatment.
| Age, Continuous(years) | 0.135mg MAP0010 | 0.25mg MAP0010 | Total |
|---|---|---|---|
| Mean | 4.6 ± 2.50 | 4.9 ± 2.03 | 4.8 ± 2.27 |
| Age, Continuous(years) | 0.135mg MAP0010 | 0.25mg MAP0010 | Total |
|---|---|---|---|
| Median | 5.0 (1 to 9) | 5.0 (1 to 8) | 5.0 (1 to 9) |
| Sex: Female, Male(Participants) | 0.135mg MAP0010 | 0.25mg MAP0010 | Total |
|---|---|---|---|
| Female | 46 | 37 | 83 |
| Male | 48 | 61 | 109 |
No study locations are listed for this record.
The record gives a start of Apr 2008, a primary completion of Aug 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide